Lupin receives EIR from US FDA for its Nagpur Injectable Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from September 8 to September 16, 2025.

Nilesh Gupta, Managing Director, Lupin, said, "We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility. We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence."

Shares of Lupin Limited was last trading in BSE at Rs. 2089.65 as compared to the previous close of Rs. 2090.15. The total number of shares traded during the day was 5652 in over 869 trades.

The stock hit an intraday high of Rs. 2100.50 and intraday low of 2078.15. The net turnover during the day was Rs. 11814457.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals EIR USFDA Nagpur InjectableFacility